Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Drug OverdoseOverdose of Beta-adrenergic Blocking Drug
Interventions
DRUG

Glucagon

"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."

DRUG

Esmolol

Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.

DRUG

Physiologic saline - glucagon dummy

Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.

DRUG

Physiologic saline - esmolol dummy

Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.

Trial Locations (1)

Unknown

University Hospital Bispebjerg, Copenhagen

All Listed Sponsors
lead

University Hospital Bispebjerg and Frederiksberg

OTHER

NCT03533179 - Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition | Biotech Hunter | Biotech Hunter